NASDAQ:LQDA Liquidia (LQDA) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free LQDA Stock Alerts $13.81 -0.04 (-0.29%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$13.50▼$13.8650-Day Range$11.96▼$15.7152-Week Range$5.71▼$16.99Volume455,956 shsAverage Volume878,241 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Liquidia alerts: Email Address Liquidia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside52.1% Upside$21.00 Price TargetShort InterestBearish10.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 11 Articles This WeekInsider TradingSelling Shares$1.13 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.26) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector465th out of 905 stocksPharmaceutical Preparations Industry221st out of 425 stocks 3.3 Analyst's Opinion Consensus RatingLiquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLiquidia has only been the subject of 2 research reports in the past 90 days.Read more about Liquidia's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.28% of the outstanding shares of Liquidia have been sold short.Short Interest Ratio / Days to CoverLiquidia has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Liquidia has recently decreased by 3.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLiquidia does not currently pay a dividend.Dividend GrowthLiquidia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LQDA. Previous Next 1.9 News and Social Media Coverage News SentimentLiquidia has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Liquidia this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,125,576.00 in company stock.Percentage Held by Insiders31.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Liquidia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Liquidia are expected to grow in the coming year, from ($1.26) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Liquidia is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Liquidia is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLiquidia has a P/B Ratio of 18.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Liquidia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Liquidia Stock (NASDAQ:LQDA)Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Read More LQDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LQDA Stock News HeadlinesJune 6, 2024 | insidertrades.comMichael Kaseta Sells 1,094 Shares of Liquidia Co. (NASDAQ:LQDA) StockJune 5, 2024 | insidertrades.comRussell Schundler Sells 710 Shares of Liquidia Co. (NASDAQ:LQDA) StockJune 6, 2024 | americanbankingnews.comLiquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 710 SharesJune 5, 2024 | americanbankingnews.comLiquidia (NASDAQ:LQDA) Shares Gap Up to $12.87June 3, 2024 | investors.comLiquidia Stock Surges After Winning Patent Battle Vs. United TherapeuticsJune 3, 2024 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Liquidia (NASDAQ:LQDA)May 29, 2024 | finance.yahoo.comLiquidia Corporation to Present at the 2024 Jefferies Global Healthcare ConferenceMay 17, 2024 | seekingalpha.comLiquidia Corp.: A Rich Catalyst Path Lies Ahead For Value UnlockingMay 15, 2024 | markets.businessinsider.comBullish Outlook for Liquidia Technologies with Buy Rating Amid Anticipated Patent Clarity and Market Growth OpportunitiesMay 15, 2024 | markets.businessinsider.comLiquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 15, 2024 | finance.yahoo.comLiquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...May 14, 2024 | finance.yahoo.comLiquidia (NASDAQ:LQDA) shareholders have earned a 64% CAGR over the last three yearsMay 14, 2024 | msn.comLiquidia GAAP EPS of -$0.54 misses by $0.24, revenue of $3M misses by $1.39MMay 14, 2024 | msn.comLQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | globenewswire.comLiquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | globenewswire.comLiquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILDMay 7, 2024 | finance.yahoo.comLiquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024May 7, 2024 | finance.yahoo.comLiquidia Corporation to Present at BofA Securities Health Care Conference 2024April 27, 2024 | nasdaq.comCommit To Buy Liquidia Corp At $10, Earn 28% Annualized Using OptionsApril 18, 2024 | investing.comLiquidia Corp CEO sells $121,888 in company stockApril 18, 2024 | investing.comLiquidia Corp executive sells shares worth over $23,000April 3, 2024 | finance.yahoo.comLiquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stakeApril 2, 2024 | globenewswire.comLiquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comBuy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ YutrepiaApril 1, 2024 | marketwatch.comLiquidia's Yutrepia Cleared for Potential FDA Approval Following Court RulingSee More Headlines Receive LQDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/11/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LQDA CUSIPN/A CIK1819576 Webwww.liquidia.com Phone(919) 328-4400FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$32.00 Low Stock Price Target$3.00 Potential Upside/Downside+53.8%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,500,000.00 Net Margins-674.42% Pretax Margin-674.42% Return on Equity-177.83% Return on Assets-78.50% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.50 Sales & Book Value Annual Sales$17.49 million Price / Sales59.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book18.70Miscellaneous Outstanding Shares76,380,000Free Float52,246,000Market Cap$1.04 billion OptionableOptionable Beta0.25 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Roger A. Jeffs Ph.D. (Age 62)CEO & Director Comp: $1.32MMr. Michael Kaseta (Age 48)COO & CFO Comp: $890.8kMr. Russell Schundler (Age 49)General Counsel & Corporate Secretary Comp: $778.49kMr. William R. Kenan Jr.Co-FounderDr. Ginger DenisonCo-FounderMs. Sarah Krepp SPHRVice President of People & CultureMr. Jason Adair (Age 52)Chief Business Officer Mr. Scott Moomaw (Age 53)Chief Commercial Officer Dr. Rajeev Saggar M.D. (Age 50)Chief Medical Officer Mr. Michael HunterSenior Vice President of Manufacturing OperationsMore ExecutivesKey CompetitorsMannKindNASDAQ:MNKDHeron TherapeuticsNASDAQ:HRTXPro-DexNASDAQ:PDEXDURECTNASDAQ:DRRXBeyond AirNASDAQ:XAIRView All CompetitorsInsiders & InstitutionsRussell SchundlerSold 710 sharesTotal: $10,330.50 ($14.55/share)Michael KasetaSold 1,094 sharesTotal: $15,917.70 ($14.55/share)Jason AdairSold 455 sharesTotal: $6,620.25 ($14.55/share)Opaleye Management Inc.Sold 50,000 shares on 5/29/2024Ownership: 0.517%Boston PartnersBought 51,642 shares on 5/28/2024Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions LQDA Stock Analysis - Frequently Asked Questions Should I buy or sell Liquidia stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LQDA shares. View LQDA analyst ratings or view top-rated stocks. What is Liquidia's stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for Liquidia's stock. Their LQDA share price targets range from $3.00 to $32.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts. How have LQDA shares performed in 2024? Liquidia's stock was trading at $12.03 on January 1st, 2024. Since then, LQDA shares have increased by 14.8% and is now trading at $13.81. View the best growth stocks for 2024 here. When is Liquidia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LQDA earnings forecast. How were Liquidia's earnings last quarter? Liquidia Co. (NASDAQ:LQDA) posted its earnings results on Monday, May, 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm had revenue of $2.97 million for the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative trailing twelve-month return on equity of 177.83%. What ETFs hold Liquidia's stock? ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Liquidia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA). When did Liquidia IPO? Liquidia (LQDA) raised $50 million in an initial public offering on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are Liquidia's major shareholders? Liquidia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Patient Square Capital LP (9.40%), Vanguard Group Inc. (3.78%), Kynam Capital Management LP (2.94%), Farallon Capital Management LLC (2.69%), Opaleye Management Inc. (0.52%) and Whitefort Capital Management LP (0.44%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Jason Adair, Michael Kaseta, Rajeev Saggar, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw. View institutional ownership trends. How do I buy shares of Liquidia? Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LQDA) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNVDA to close the AI “wealth window’ June 25?On Tuesday, June 25, in front of executives from nearly every major tech company in existence, key leaders at ...Paradigm Direct | Sponsored"If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.""I'd Feel Secure Putting 50% of My Kids' Inheritance in THIS Stock" One Wall Street millionaire bought AAPL...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liquidia Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liquidia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.